Ultralife Stock Forecast, Price & News

Ultralife (NASDAQ:ULBI) Frequently Asked Questions

Is Ultralife a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ultralife in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Ultralife stock.
View analyst ratings for Ultralife or view top-rated stocks.

How has Ultralife's stock been impacted by Coronavirus (COVID-19)?

Ultralife's stock was trading at $6.44 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ULBI shares have decreased by 14.1% and is now trading at $5.53.
View which stocks have been most impacted by COVID-19.

When is Ultralife's next earnings date?

Ultralife is scheduled to release its next quarterly earnings announcement on Thursday, February 3rd 2022.
View our earnings forecast for Ultralife.

How were Ultralife's earnings last quarter?

Ultralife Co. (NASDAQ:ULBI) announced its earnings results on Thursday, October, 28th. The technology company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of $0.08 by $0.12. The technology company earned $21.76 million during the quarter. Ultralife had a net margin of 2.90% and a trailing twelve-month return on equity of 3.13%.
View Ultralife's earnings history.

What price target have analysts set for ULBI?

1 Wall Street analysts have issued 12-month price objectives for Ultralife's shares. Their forecasts range from $12.00 to $12.00. On average, they anticipate Ultralife's stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 117.0% from the stock's current price.
View analysts' price targets for Ultralife or view top-rated stocks among Wall Street analysts.

Who are Ultralife's key executives?

Ultralife's management team includes the following people:

• Michael D. Popielec, President, Chief Executive Officer & Director
• Philip A. Fain, Chief Financial Officer, Secretary & Treasurer

Who are some of Ultralife's key competitors?

Some companies that are related to Ultralife include Ivanhoe Capital Acquisition (IVAN), CBAK Energy Technology (CBAT), Sono-Tek (SOTK), Flux Power (FLUX), Evercel (EVRC), Polar Power (POLA), mPhase Technologies (XDSL), Manhattan Scientifics (MHTX), TNR Technical (TNRK), Lightscape Technologies (LTSCD), Isomet (IOMT), AER Energy Resources (AERN), Axion Power International (AXPWQ), Environmental Tectonics (ETCC) and Evans & Sutherland Computer (ESCC).
View all of ULBI's competitors.

What other stocks do shareholders of Ultralife own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ultralife investors own include (CGC), Sociedad Química y Minera de Chile (SQM), Aurora Cannabis (ACBFF), OPKO Health (OPK), Aurora Cannabis (ACB), Arotech (ARTX), Antares Pharma (ATRS), Enterprise Products Partners (EPD), Verizon Communications (VZ) and Teva Pharmaceutical Industries (TEVA).

What is Ultralife's stock symbol?

Ultralife trades on the NASDAQ under the ticker symbol "ULBI."

Who are Ultralife's major shareholders?

Ultralife's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Dimensional Fund Advisors LP (6.88%), Monarch Partners Asset Management LLC (2.34%), Janney Montgomery Scott LLC (2.22%), Victory Capital Management Inc. (2.10%), Renaissance Technologies LLC (1.53%) and Russell Investments Group Ltd. (1.01%). Company insiders that own Ultralife stock include Bradford T Whitmore, Philip A Fain and W Shaw Robert.
View institutional ownership trends for Ultralife.

Which institutional investors are selling Ultralife stock?

ULBI stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Renaissance Technologies LLC, Allianz Asset Management GmbH, Russell Investments Group Ltd., Victory Capital Management Inc., Dimensional Fund Advisors LP, and BlackRock Inc..
View insider buying and selling activity for Ultralife or view top insider-selling stocks.

Which institutional investors are buying Ultralife stock?

ULBI stock was bought by a variety of institutional investors in the last quarter, including Monarch Partners Asset Management LLC, Janney Montgomery Scott LLC, and Geode Capital Management LLC. Company insiders that have bought Ultralife stock in the last two years include Bradford T Whitmore, Philip A Fain, and W Shaw Robert.
View insider buying and selling activity for Ultralife or or view top insider-buying stocks.

How do I buy shares of Ultralife?

Shares of ULBI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ultralife's stock price today?

One share of ULBI stock can currently be purchased for approximately $5.53.

How much money does Ultralife make?

Ultralife has a market capitalization of $88.93 million and generates $107.71 million in revenue each year. The technology company earns $5.23 million in net income (profit) each year or $0.18 on an earnings per share basis.

How many employees does Ultralife have?

Ultralife employs 532 workers across the globe.

Does Ultralife have any subsidiaries?

The following companies are subsidiares of Ultralife: ABLE New Energy Co. Limited, Accutronics Ltd., CLB Inc., Southwest Electronic Energy Corporation, Ultralife Batteries (UK) LTD, Ultralife Batteries India Private Limited, Ultralife Energy Services Corporation, and Ultralife UK LTD.

When was Ultralife founded?

Ultralife was founded in 1990.

What is Ultralife's official website?

The official website for Ultralife is www.ultralifecorporation.com.

Where are Ultralife's headquarters?

Ultralife is headquartered at 2000 TECHNOLOGY PARKWAY, NEWARK NY, 14513.

How can I contact Ultralife?

Ultralife's mailing address is 2000 TECHNOLOGY PARKWAY, NEWARK NY, 14513. The technology company can be reached via phone at (315) 332-7100 or via fax at 315-331-7800.